This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Strength Seen in Owens & Minor (OMI): Can Its 36.2% Jump Turn into More Strength?
by Zacks Equity Research
Owens & Minor (OMI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.
Abbott (ABT) Organic Growth Strong, Pediatric Nutrition Down
by Zacks Equity Research
Within Medical Device, Abbott (ABT) is facing challenging conditions in terms of procedure volume.
Here's Why You Should Hold On to Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on solid first-quarter results and a gradually stabilizing global musculoskeletal market.
6 Valuable Price-to-Book Stocks to Boost Your Portfolio
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Top Ranked Growth Stocks to Buy for May 21st
by Zacks Equity Research
COLM, OMI, AN, and HRI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 21, 2021
Add These 5 Low P/CF Stocks to Create a Value-Based Portfolio
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Boise Cascade Company (BCC), Vishay Intertechnology (VSH), Owens & Minor (OMI), Sanmina Corporation (SANM) and Invesco (IVZ) boast low P/CF ratio.
LabCorp's (LH) New Bioanalytical Lab to Boost APAC Operation
by Zacks Equity Research
The new laboratory by LabCorp (LH) is set to enable faster data turnaround for early phase trials in Asia-Pacific markets.
Thermo Fisher (TMO) to Boost Cell Therapies With UCSF Deal
by Zacks Equity Research
Thermo Fisher's (TMO) collaboration with UCSF will enable end-to-end solution to accelerate cell therapy development and manufacturing with new facility.
TeleFlex (TFX) Urolift Grows, Organic Sales Hit by Pandemic
by Zacks Equity Research
On the strength of a successful 2020 campaign, Teleflex (TFX) doubles the awareness for UroLift in the targeted population of men with BPH.
LabCorp's (LH) Pixel Kit Gets EUA for Younger Population
by Zacks Equity Research
LabCorp (LH) becomes the first major commercial laboratory to offer a COVID-19 PCR Test Home Collection Kit for children and adolescents.
Abbott (ABT) Receives CE Mark for Latest Navitor TAVI System
by Zacks Equity Research
Abbott's (ABT) latest-generation Navitor TAVI system features improvements to reduce or eliminate a backflow of blood around valve implants.
Here's Why You Should Buy Henry Schein (HSIC) Stock Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) on solid first-quarter performance and strategic deals.
Is Owens & Minor (OMI) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for May 17th
by Zacks Equity Research
AOSL, DIOD, LL, OMI, and RUSHA have been added to the Zacks Rank #1 (Strong Buy) List on May 17, 2021
Medtronic's (MDT) Coronary Market Share Grows Amid Pandemic
by Zacks Equity Research
In Gastrointestinal, Medtronic (MDT) is witnessing some modest share gains, driven in part by its partnership with the NHS in England.
Top Ranked Growth Stocks to Buy for May 17th
by Zacks Equity Research
LL, OMI, LB, and AN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 17, 2021
Top Ranked Value Stocks to Buy for May 17th
by Zacks Equity Research
AAWW, OMI, MCBS, and SBLK made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 17, 2021
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on strong quarterly results and robust pump sales.
Tandem (TNDM) Global Growth Strong, Costs Continue to Rise
by Zacks Equity Research
Tandem Diabetes (TNDM) is witnessing high international demand for the t:slim X2 pump.
Here's Why You Should Buy Amedisys (AMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Amedisys (AMED) on bright Personal Care prospects, and strategic acquisitions and partnerships.
Amedisys (AMED) to Buy VNA Hospice, Home Health, Expand in NE
by Zacks Equity Research
The acquisition is going to expand Amedisys' (AMED) presence in Omaha and Council Bluffs' healthcare communities.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) owing to its solid first-quarter performance and impressive value-added acquisitions.
Design a Balanced Portfolio With These 5 Low P/CF Stocks
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Vishay Intertechnology (VSH), Boise Cascade (BCC), Owens & Minor (OMI), ON Semiconductor (ON) and Sanmina (SANM) boast low P/CF ratio.
Owens & Minor (OMI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Owens & Minor (OMI) closed at $33.41 in the latest trading session, marking a -2.62% move from the prior day.